CROs & CMOs
Contract research organisations (CROs) and contract manufacturing organisations (CMOs) are among the strongest growth sectors of the pharmaceutical industry, with many firms experiencing double-digit annual growth. We work with CROs and CMOs in organisation asset restructuring and building core divisions through M&A activity.
Our team has a strong track-record having advised on some of the most important deals in the space including INC Research on its merger with inVentiv, GHO Capital on its acquisition of Sterling Pharma and Linguamatics on its acquisition by IQVIA.
A combination of our deep sector knowledge and long-standing industry relationships enables us to get the best outcomes for our clients.
CROs & CMOs Deals
CRO Sector Update: March 2021
M&A and valuations in the CRO sector – March 2021 The level of impact that Covid-19 has had on M&A activity is comparable to that of the Great Financial Crisis, however, the rebound has been notably stronger. In the last year c.70 deals completed with a significant contribution from the second half of the year. […]
Cell and Gene Therapies: Challenges in Scale-up to Commercial Manufacturing
The cellular therapy and gene therapy fields are undergoing very rapid growth. This includes a large and growing number of products in the development pipeline, and new products with significant sales, including blockbusters, now entering world markets. Billions are being invested in research and commercial development with markets in $10s of billions expected in the […]
Blockchain applications in clinical trials and the impact of COVID-19
Blockchain technology first came on the scene in 2017. Since then it has generated high expectations: blockchain applications in clinical trials have always had the potential to automate outdated ways of working and rapidly piece together disparate data sets, in a secure and auditable manner. Somehow, it seems as if blockchain failed to live up […]